Physician profile
Philip J Suh
NPI 1518934009
$298,877.66
in general payments reported to CMS, 2019-2025
55 companies · $46K in 2025
The $46K reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $37K · 2021: $34K · 2022: $26K · 2023: $14K · 2024: $32K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Food and Beverage: $21K · Travel and Lodging: $5,551 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,224.37 |
| Food and Beverage | $20,999.97 |
| Travel and Lodging | $5,550.92 |
| Education | $118.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100,807.85 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $33,324.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $31,544.91 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Amarin Pharma, INC. | $29,772.34 | 2019-2023 | |
| Abbvie INC. | $25,542.08 | 2019-2025 | Creon, Linzess, Viberzi |
| Janssen Pharmaceuticals, INC | $24,305.28 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $14,203.43 | 2021-2025 | |
| Eisai INC. | $8,299.47 | 2020-2022 | |
| Genentech USA, INC. | $5,886.92 | 2019-2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,116.63 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Glaxosmithkline, LLC. | $3,099.99 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Lilly USA, LLC | $3,025.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Genentech, INC. | $1,870.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,326.30 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $1,220.38 | 2019-2025 | Zoryve, Seglentis, Livalo |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,204.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,182.49 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $1,078.29 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Allergan, INC. | $819.40 | 2019-2022 | |
| Horizon Therapeutics Plc | $789.50 | 2019-2023 | Krystexxa, Tepezza |
| Arbor Pharmaceuticals, INC. | $631.90 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $591.52 | 2019-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $509.36 | 2019-2025 | Ajovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $497.59 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $328.05 | 2022-2024 | Rexulti |
| Gilead Sciences, INC. | $314.16 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $314.10 | 2022 | |
| Corcept Therapeutics | $306.95 | 2019-2025 | Korlym |
| Astellas Pharma US INC | $304.14 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $301.63 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $296.63 | 2019-2020 | |
| Esperion Therapeutics, INC. | $283.38 | 2020-2025 | Nexletol |
| Dexcom, INC. | $217.34 | 2023-2024 | Dexcom G6 Transmitter |
| Medicure Pharma INC. | $192.12 | 2020-2021 | |
| Genzyme Corporation | $185.91 | 2022-2025 | |
| Penumbra, INC. | $137.23 | 2024 | Indigo System |
| Lundbeck LLC | $132.42 | 2021-2025 | Rexulti |
| Lexicon Pharmaceuticals, INC. | $126.96 | 2023-2024 | Inpefa |
| Idorsia Pharmaceuticals US INC | $109.27 | 2022-2023 | Quviviq |
| Boston Scientific Corporation | $103.53 | 2023 | Wavewriter Alpha Prime 16 |
| Nestle Healthcare Nutrition INC. | $77.97 | 2021 | |
| Avanir Pharmaceuticals, INC. | $72.69 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $71.21 | 2021 | |
| Abbott Laboratories | $69.92 | 2025 | Freestyle Libre 3 |
| Leo Pharma INC. | $68.70 | 2021-2025 | Anzupgo |
| Verity Pharmaceuticals INC. | $39.03 | 2025 | Tlando |
| Axsome Therapeutics, INC. | $35.44 | 2025 | Auvelity |
| Arcutis Biotherapeutics, INC. | $25.57 | 2024 | Zoryve |
| Aimmune Therapeutics, INC. | $23.11 | 2025 | Zenpep |
| Insulet Corporation | $17.23 | 2023 | Omnipod |
| Adlon Therapeutics L.P. | $16.33 | 2021 | |
| Exact Sciences Corporation | $16.01 | 2025 | The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $14.63 | 2024 | Givlaari |
| Azurity Pharmaceuticals, INC. | $14.41 | 2023 | Edarbi |
| Endo Pharmaceuticals INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.